Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

mercaptopurine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor, PRPP amidotransferase inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1
NT5C2 mutation	Acute Lymphocytic Leukemia	NT5C2 mutation	Acute Lymphocytic Leukemia	mercaptopurine Resistant: D – Preclinical mercaptopurine Resistant : D	mercaptopurine Resistant: D – Preclinical mercaptopurine Resistant : D
NT5C2 R367Q	T Acute Lymphoblastic Leukemia	NT5C2 R367Q	T Acute Lymphoblastic Leukemia	mercaptopurine Resistant: D – Preclinical mercaptopurine Resistant : D	mercaptopurine Resistant: D – Preclinical mercaptopurine Resistant : D